Page last updated: 2024-11-05

trimetrexate and Rheumatoid Arthritis

trimetrexate has been researched along with Rheumatoid Arthritis in 1 studies

Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.

Research Excerpts

ExcerptRelevanceReference
"Although methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA), patients experience clinical resistance to MTX upon prolonged treatment."3.80Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients. ( Assaraf, YG; Dijkmans, BA; Gerards, AH; Jansen, G; Lems, WF; Oerlemans, R; Scheper, RJ; van der Heijden, JW, 2014)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
van der Heijden, JW1
Assaraf, YG1
Gerards, AH1
Oerlemans, R1
Lems, WF1
Scheper, RJ1
Dijkmans, BA1
Jansen, G1

Other Studies

1 other study available for trimetrexate and Rheumatoid Arthritis

ArticleYear
Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.
    Scandinavian journal of rheumatology, 2014, Volume: 43, Issue:1

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Folic Acid Antagonists; Humans; Male; Methotrex

2014